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ABSTRACT
Purpose: This study examined the efficacy and safety of selexipag in treating pulmonary arterial hypertension
(PAH) associated with congenital heart disease (CHD). Materials and Methods: We conducted a retrospective
study of patients with CHD-associated PAH, treated with selexipag since December 2017. Thirteen adult patients
(mean age, 45.4 years; women, 77%) were treated with selexipag as add-on therapy. Baseline characteristics,
World Health Organization functional class, 6-minute walking distance (6MWD) test results, N-terminal pro-
B-type natriuretic peptide levels, echocardiographic data, and incidence of side effects were assessed. Results:
The majority of patients (12/13, 92.3%) experienced more than one treatment-associated complication; one
patient dropped out of the study due to intolerable myalgia. The results of 6MWD test (from 299.2 ± 56.2 m
to 363.8 ± 86.5 m, p = 0.039) and tricuspid regurgitation (TR) pressure gradient (from 84.7 ± 20.5 mmHg to
61.6 ± 24.0 mmHg, p = 0.018) improved and remained improved after selexipag treatment in 12 patients. Based
on the results of a non-invasive risk assessment, 8 (66.7%) patients showed improvement, 3 (25.0%) showed no
interval change, and the status of one patient (8.3%) deteriorated. Moreover, compared to patients treated with a
low dosage, patients treated with a medium-to-high dosage showed a greater increase in 6MWD results (88.3 ±
26.4 m vs. 55.3 ± 27.6 m, p = 0.043) and a greater reduction in the TR pressure gradient (-33.7 ± 10.9 mmHg vs.
-12.5 ± 12.0 mmHg, p = 0.015). Conclusion: Selexipag is an efficient pulmonary vasodilator as add-on therapy in
treating CHD-associated PAH.
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1 Introduction
Pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) (PAH-CHD) is
one of the most common types of PAH [1–3]. Recent progress in medical and surgical treatment of CHD
means that nowadays most affected patients survive into adulthood [4], leading to an increase in the
prevalence of PAH-CHD. The prevalence of PAH among adult patients with CHD is estimated to be 5–
10%, depending on the underlying shunt size and location and complexity of the CHD [5]. PAH-CHD
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stratified by shunt lesions consists of heterogeneous subgroups [6,7], as follows: (1) Eisenmenger syndrome,
(2) PAH associated with predominant systemic-to-pulmonary shunts (either correctable or not), (3) PAH with
small/coincidental defects, and (4) PAH after repair (corrected PAH-CHD). Treatment of PAH-CHD requires
a delicate and meticulous approach by PAH-CHD experts, including precise early diagnosis of CHD and
confirmation of PAH-CHD, including operability, based on the results of pulmonary vascular resistance
and vasoreactive tests. Timely corrective surgery or intervention is imperative in operable PAH-CHD, and
staged palliation for further definitive treatment is crucial in the treatment of complex or borderline PAH-
CHD. Targeted PAH therapy and suitable supportive care, including diuretics, oxygen supplementation,
and the use of appropriate anti-coagulation agents are important at every strategic point in-patient care
[7]. Recent guidelines recommend sequential or upfront use of a combination of selective PAH drugs,
targeting endothelin, nitric oxide, and prostacyclin pathways [8]. Selexipag (Uptravi, Actelion
Pharmaceuticals) is a highly selective, oral, long-acting prostacyclin receptor (IP receptor) agonist [9,10].
It was approved by the Food and Drug Administration in December 2015 and by the European
Medicines Agency in May 2016, allowing for marketing of an oral combination therapy, targeting the
prostacyclin pathway. A phase III trial (GRIPHON) has shown that, compared to placebo, selexipag
reduced the risk of mortality or major complications associated with PAH [11] and improved the results
of a 6-minute walking distance test. Thereafter, many studies have demonstrated the clinical efficacy and
tolerability in various patient groups, including patients with connective tissue disease [12,13], chronic
pulmonary thromboembolism [14], as well as pediatric populations [15]; heterogeneous real-life data also
appear to support the clinical trial findings [16]. Regarding treatment of PAH-CHD, post-hoc analysis of
the GRIPHON study data has demonstrated that selexipag may delay disease progression and is well-
tolerated [17]; however, this trial only included corrected PAH-CHD patients. Thus, the clinical efficacy
and safety of selexipag among patients with PAH-CHD requires elucidation. This study examined the
efficacy and safety of selexipag in PAH-CHD patients, including patients with Eisenmenger syndrome
and partially repaired CHD.
2 Materials and Methods
Adult patients (age >18 years), prescribed selexipag, from December 2017 to August 2019 at the
Division of Pediatric Cardiology, Congenital Heart Center, Severance Cardiovascular Hospital, a tertiary
university hospital, were retrospectively screened and enrolled in this study. Patients with PAH-CHD,
previously confirmed by right heart catheterization, were included; patients with idiopathic PAH was
excluded. At baseline, all patients were treated with all types of PAH drugs, except prostanoids; selexipag
was added to the baseline PAH-targeting drug.
The Institutional Review Board of Severance Hospital (4-2019-1083) approved the study protocol, and
this study was performed in accordance with the Declaration of Helsinki; the requirement for acquisition of
informed consent was waived owing to the study’s retrospective nature.
Although this study was performed retrospectively, our clinical policy strictly followed the relevant PAH
management guidelines [8]. Right heart catheterization was performed using a Berman or Swan-Ganz
catheter, and cardiac output was measured by thermodilution. The pulmonary vasoreactivity test was
performed using inhaled O2 and iloprost. According to the guidelines on the pulmonary vascular
resistance index, the values >8 Wood unit (WU)*m2 were indicative of inoperable cases [8,18]. In
patients with borderline PAH (pulmonary vascular resistance index range, 4–8 WU*m2) with an atrial
septal defect (ASD), treatment modalities (surgery vs. interventions, and approaches with vs. without
fenestration) were discussed and decided on in a multidisciplinary team meeting. When indicated,
transcatheter closure of the atrial septal defect was performed, as previously reported. [19,20] Temporary
balloon occlusion test was performed for additional information of reversibility of PAH as well as testing
for masked left ventricular restriction in patients with ASD.
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Except for patients with an atrial septal defect, all patients with CHD had Eisenmenger syndrome. ASD
patients with acceptable range of PAH were treated either completely repaired (N = 1) or partially repaired
with fenestration (N = 5). However, one patient with uncorrectable PAH was not repaired, and has been
treated with PAH drugs and will be analyzed by further catheterization, which is so called “PAH treat and
repair strategy” [21]. Selexipag treatment was initiated at a dose of 200 µg twice daily which was
increased weekly or biweekly in increments of 200 µg twice daily until unmanageable side effects
developed. When unmanageable side effects developed, the dose was decreased by 200 µg twice daily.
Up-titration was resumed once side effects had subsided or become tolerable; nevertheless, increases were
administered at a slower rate. If intolerable and untreatable side effects recurred, the dose was decreased
by 200 µg once or twice daily, and the adjusted dose was regarded as the maintenance dose. We
prescribed supportive analgesics (ibuprofen) in all cases as well as antiemetic (metoclopramide) and
antidiarrheal drugs (loperamide), as required. All supportive drugs were prescribed at their usual dosage
and increased to the maximal dosage, as required and indicated.
Baseline characteristics, hemodynamic and echocardiographic data, World Health Organization
functional class, 6-minute walking distance test results, and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels were assessed. Data from the last available right heart catheterization measurement
were adopted as the baseline. Patients were followed up every 1–4 weeks during selexipag dose titration
and every 3–6 months thereafter. Side effects of selexipag and World Health Organization functional class
were assessed at every clinic visit by the attending physician. The 6-minute walking distance test was
performed according to the American Thoracic Society guidelines [22]. Transthoracic echocardiography
was performed in supine and left lateral decubitus positions; the basic 2-dimensional and M-mode
echocardiography, and continuous wave and tissue Doppler data were obtained. Data on
echocardiographic prognostic markers of PAH such as the pressure gradient of tricuspid regurgitation,
tricuspid annular plane systolic excursion of the right atrial area, and presence of pericardial effusion
were collected. The doppler image of tricuspid regurgitation was obtained well before and after selexipag
treatment in all patients, which might be related with patient characteristics who had severe PAH and at
least mild tricuspid regurgitation.
Risk assessment was based on non-invasive methods, as defined in the French registry, and involved the
following parameters: Low risk was defined as World Health Organization functional class I–II, 6-minute
walking distance >440 m, and NT-proBNP <300 ng/L [23,24].
2.1 Statistical Analysis
The D’Agostino-Pearson test was used to verify the normality of distribution assumption of continuous
variables. Normally distributed continuous variables were reported as means and standard deviations,
whereas their non-normally distributed counterparts were expressed as medians with ranges. Categorical
variables were expressed as counts (percentages). Changes from baseline to follow-up measurements of
variables of interest were assessed using the chi-squared test, paired t-test, or Wilcoxon test, as suitable,
and a 2-tailed p-value <0.05 was considered statistically significant. Statistical analysis was performed
using SPSS version 25.0 (IBM Corp., Armonk, NY, USA).
3 Results
A total of 14 patients were treated with selexipag at our department; a single patient with idiopathic PAH
was excluded from this study. The baseline characteristics of the enrolled patients are summarized in (Tab. 1).
Patients were either World Health Organization functional class II (38.5%) or III (61.5%). All patients were
already being treated with PAH drugs; 12 patients were receiving monotherapy, (with an endothelin receptor
antagonist and a phosphodiesterase type 5 inhibitor prescribed to 9 and 3 patients, respectively) and 1 was on
dual therapy. The median treatment duration was 49 months (range, 3–120 months). There were no
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differences in sex, age, World Health Organization functional class, or baseline PAH drug use between
patients with and without Eisenmenger syndrome (data not shown). No patients died during the study
period or were lost to follow-up.
Table 1: Baseline and hemodynamic characteristics of patients (n = 13)
Characteristics n = 13
Age (years) 45.4 ± 12.8
Female (n [%]) 10 (76.9)
BMI (kg/m2) 20.3 ± 6.7




DORV with VSD 1 (7.7)
ccTGA with VSD 1 (7.7)
Current status (n [%])
Eisenmenger syndrome 6 (46.2)
Complete repair 1 (7.7)
Partial repair with fenestration 5 (38.5)
Surgical repair with fenestration 2 (15.4)
Transcatheter closure with fenestration 3 (23.1)
Treat and repair strategy 1 (7.7)




PDE-5 inhibitor 3 (23.1)
ERA + PDE-5 inhibitor 1 (7.7)
Duration before selexipag (months) 49.3 (3–120)
sPAP (mmHg) 100.4 ± 20.8
mPAP (mmHg) 61.8 ± 21.2
mRAP (mmHg) 12.3 ± 4.3
PVRi (Wood unit*m2) 10.1 ± 3.3
Selexipag duration (months) 14.7 (3–20)
Normally distributed data are expressed as mean ± standard deviation; non-normally
distributed data are presented as median (range). Discrete data are expressed as count
(percentage).
Abbreviations: ASD, atrial septal defect; BMI, body mass index; ccTGA, congenitally
corrected transposition of the great artery; CHD, congenital heart disease; DORV, double
outlet right ventricle; ERA, endothelin receptor antagonist; mPAP, mean pulmonary artery
pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; PDA,
patent ductus arteriosus; PDE-5, phosphodiesterase type 5; PVRi, pulmonary vascular
resistance; sPAP, systolic pulmonary artery pressure; VSD, ventricular septal defect.
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In the present study, no patient reached the maximal maintenance dosage of selexipag (mean, 1166 µg/
day), as the majority of patients (92.3%) experienced more than 1 side effect. The maximal maintenance
dosage was low (<1000 µg/day) in 41.6% of patients, medium (1000–2000 µg/day) in 50% of patients,
and high (>2000 µg/day) in one (8.4%) (Fig. 1a). After adjustment for weight, half of the patients
reached a dosage of 20–60 µg/kg/day (Fig. 1b).
In the present study, the most common side effect was musculoskeletal pain, followed by headache, and
nausea and diarrhea (Fig. 2). No unexpected side effects were reported. One patient with a ventricular septal
defect and Eisenmenger syndrome suffered due to intolerable myalgia, resulting in drug discontinuation and
exclusion from the present study’s analysis of efficacy and risk reassessment. One patient, who was
previously diagnosed with rheumatic arthritis and had suffered from arthralgia prior to selexipag
initiation, could not bear the dosage titration, resulting in a maintenance dosage of 400 µg/day.
Following exclusion of one patient due to selexipag discontinuation, 12 patients in total were included in
the efficacy analysis. Follow-up (FU) assessment was performed at 12.3 ± 2.8 months after selexipag
Figure 1: Individual maintenance dosage of selexipag (A) and weight-adjusted dosage (B) (n = 12)
Figure 2: Percentage of patients experiencing different side effects associated with selexipag treatment
(n = 13)
CHD, 2021, vol.16, no.3 237
initiation. After selexipag treatment, the results of the 6-minute walking distance test increased (from 299.2 ±
56.2 m to 363.8 ± 86.5 m, p = 0.039; Fig. 3a) and the tricuspid regurgitation pressure gradient decreased
(from 84.7 ± 20.5 mmHg to 61.6 ± 24.0 mmHg, p = 0.018; Fig. 3b). Concurrently, NT-proBNP levels
decreased (from 1580 ± 497 pg/mL to 629 ± 220 pg/mL, p = 0.096; Fig. 3c); however, this change was
not statistically significant. Furthermore, World Health Organization functional class improved in
5 patients and remained stable in 7 patients. The tricuspid annular plane systolic excursion and right
atrium fractional area change showed no relevant changes.
Figure 3: Changes in clinical parameters after selexipag treatment: (A) 6-minute walking distance (6MWD),
(B) tricuspid regurgitation (TR) pressure gradient, and (C) N-terminal pro-B-type natriuretic peptide
(NT-proBNP)
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Changes in the risk assessment, based on the French registry group [23], between baseline and follow-up
are presented in Fig. 4. Among individual patients, 8 (66.7%) showed improvement, 3 (25.0%) showed no
change, and 1 (16.7%) showed worsening at the time of risk reassessment. Individual profiles of risk
assessment before and after selexipag was described in (Tab. 2). Among 5 patients with Eisenmenger
syndrome, 2 showed improvement in 6-minute walking distance scores (n = 1) and NT-proBNP levels
(n = 1), whereas the remaining 3 exhibited no change. As for patients without Eisenmenger syndrome,
improvement was observed in 6 cases, and a single patient experienced worsening.
Compared to the low dosage group (n = 5), the medium-to-high maintenance dosage group (n = 7)
showed a significant change in 6-minute walking distance scores (88.3 ± 26.4 m vs. 55.3 ± 27.6 m,
p = 0.043, Fig. 5a) and tricuspid regurgitation pressure gradient (−33.7 ± 10.9 mmHg vs. −12.5 ±
12.0 mmHg, p = 0.015, Fig. 5b). Concurrently, there was no difference in the change in NT-proBNP
levels between the groups (Fig. 5c). Nevertheless, the maintenance dosage did not seem to affect the
patients’ PAH status, irrespective of the presence of Eisenmenger syndrome (1371 ± 558 in non-
Eisenmenger vs. 880 ± 334 in Eisenmenger, p = 0.112).
4 Discussion
The present study reported real-life outcomes of selexipag treatment among PAH-CHD patients,
including patients with Eisenmenger syndrome and partially repaired CHD. Previous studies have
reported on the successful initiation of selexipag and functional improvement in 4 patients with
Eisenmenger syndrome [25] and complex CHD [15]. In the present study, we have included the
assessment of selexipag efficacy at improving or at least stabilizing the status of patients with
Eisenmenger syndrome or partially repaired CHD.
In the present study, all patients were alive at the end of the study period, and no life-threatening adverse
effects were observed. Side effects observed in the present study were consistent with previous reports
[11,16]. As in the previous studies, in the present study, the majority of patients experienced side effects.
Figure 4: Changes in the assessed risk after selexipag treatment using 3 non-invasive parameters: 6-minute
walking distance, World Health Organization functional class, and N-terminal pro-B-type natriuretic peptide.
The number of parameters in the low-risk group is counted for each patient. Low risk criteria was defined as
World Health Organization functional class I–II, 6-minute walking distance >440 m, and NT-proBNP
<300 ng/L, respectively [23]. Green, blue, and red arrows indicate clinical improvement, no interval
change, and worsening, respectively
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The maintenance dose in the present study was lower than that reported in previous studies [11,16]. A
separate study involving Japanese patients has reported a relatively lower maintenance dose [26]. These
discrepancies in dosage might be related to several factors: (1) There is a lack of specialist nursing care to
encourage uptake of this treatment among patients; (2) The cost-benefit ratio, particularly among patients
with long-term severe PAH, is inadequate, and the concurrent use of selexipag results in marked relief
from PAH symptoms even at a low dose required to control side effects; and (3) The optimal dosage for
underweight patients or patients who belong to other ethnic groups requires further research.
The present study has shown a marked improvement in the 6-minute walking distance test and a
reduction in tricuspid regurgitation pressure gradient despite a relatively lower maintenance dosage. This
finding might be accounted for by the study sample characteristics. Other studies have performed dose
Figure 5: Comparison of changes in parameters before and after selexipag treatment stratified according to
maintenance dosage (low vs. medium-to-high): (a) 6MWD, (b) TR pressure gradient, and (c) NT-proBNP
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escalation even in low-risk groups, when the patients could not fulfill the low risk criteria [14]. In the present
study, we tended to add selexipag to the regimen of patients with extreme PAH, as sequential add-on therapy
is approved by the Korean National Health Insurance Review and Assessment Service for cases involving
clinical and/or hemodynamic worsening of PAH but not in cases that do not achieve an improvement in
clinical or hemodynamic status during risk assessment (Tab. 3). Low baseline 6-minute walking distance
scores and high NT-proBNP levels in this study reflect the clinical status of our patients, as a recent study
has shown that a high NT-proBNP level is associated with poor clinical outcomes among PAH patients [27].
A recent post-hoc analysis of the GRIPHON study data has shown the relationship between risk profile
and mortality/morbidity among PAH patients [24], demonstrating the benefits of selexipag at improving risk
profile even among patients with corrected CHD. The present study adds to the body of clinical evidence,
showing the impact of selexipag on improving risk profiles even among patients with Eisenmenger
syndrome or partially repaired CHD.
Dose-related efficacy was not evident in the previous real-life study on selexipag; however, it was
detected in the present study despite a small number of patients. Nevertheless, this phenomenon should
be further investigated in a larger cohort.
5 Limitations
This study was a non-randomized retrospective study with some inherent limitations. Moreover, follow-
up right heart catheterization data were only available for 3 patients due to the relative shortness of the
follow-up period and invasiveness of the test, resulting in right heart catheterization data being excluded
from the analysis in the present study. The cardiopulmonary exercise test was performed in selective
cases and not included in the present report. Reported clinical improvement might be exaggerated by a
combination of a small number of included patients and biases associated with the treatment of high-risk
patients. Nevertheless, the clinical efficacy of selexipag as add-on therapy in the present group of high-
risk patients is evident as the included high-risk group had severe PAH-CHD despite long-term treatment
with PAH drug(s) prior to study enrollment.
Table 3: Current reimbursement guideline approved by the Korean National Health Insurance Review and
Assessment Service for sequential combination treatment of pulmonary arterial hypertension
Indicators Criteria
1. Clinical evidence of RV failure +
2. Rate of progression of symptoms Rapid
3. Syncope +
4. WHO FC WHO FC IV
5. 6MWD <300 m
6. Cardiopulmonary exercise testing Peak O2 consumption <12 mL/min/kg
7. BNP/NT-proBNP plasma levels >300/1800 ng/L
8. Echocardiographic findings Pericardial effusion or TAPSE <1.5 cm
9. Hemodynamics RAP >15 mmHg or CI ≤2.0 L/min/m2
Sequential combination therapy is accepted in cases of no clinical or hemodynamic improvement, defined as
meeting at least one of criteria 1–4 and at least one of criteria 5–9 after at least 3 months of treatment.
Abbreviations: 6MWD, 6-minute walking distance; BNP, B-type natriuretic peptide; CI, cardiac index; FC,
functional class; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RAP, right atrium pressure; RV, right
ventricle; TAPSE, tricuspid annular plane systolic excursion; WHO, World Health Organization.
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6 Conclusions
The present study contributes to the evidence on the clinical efficacy of selexipag as add-on therapy
in the real-life treatment of patients with PAH-CHD, including Eisenmenger syndrome and partially
repaired CHD.
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